


# CMR for Regurgitant Valve Lesions

Dipan J. Shah, MD, FACC  
Professor of Medicine, Weill Cornell Medical College  
Director, Cardiovascular Imaging Institute  
Director, Cardiovascular MRI Laboratory  
Houston Methodist DeBakey Heart & Vascular Center


HOUSTON  
**Methodist**  
DEBAKEY HEART &  
VASCULAR CENTER

 @dipanjsah


## Sequences Needed:

### CMR For Valve Assessment


Cine-CMR: LV/RV Stroke Volume



Phase Contrast CMR: Great Vessel Flow



## Conservation of Flow Principle




$$LVS\!V = RVS\!V = AO\ Flow = PA\ Flow$$

## OUTLINE:

- What are the goals of CMR in valve assessment ?
  - Severity of lesion
  - Mechanism of lesion
  - Consequences of lesion
- How does CMR compare to Echo
- When to use CMR for valve assessment









## OUTLINE:



[www.med.uottawa.ca](http://www.med.uottawa.ca)

## 40 year old woman referred for evaluation of murmur.






## OUTLINE:


- How does CMR assess valve regurgitation ?
  - Severity of lesion
  - Mechanism of lesion
  - Consequences of lesion
- How does CMR compare to Echo for regurgitation assessment
- When to use CMR for valve regurgitation



## Mechanism of MR:



## Mechanism of MR:



CMR is inferior to TEE in depicting torn chordae.

		Sensitivity	Specificity	Accuracy
AML	TEE (n=36)	75	96	92
	MRI (n=35)	71	96	91
PML	TEE (n=36)	86	93	89
	MRI (n=35)	86	100	91


Stork A.Eur Radiol (2007) 17: 3189-3198

## OUTLINE:


- How does CMR assess valve regurgitation ?
  - Severity of lesion
  - Mechanism of lesion
  - Consequences of lesion
    - LV Enlargement
    - LV Dysfunction
    - LA Enlargement
    - Myocardial Fibrosis



## Fibrosis in Mitral Valve Prolapse




**CENTRAL ILLUSTRATION:** Prevalence of Replacement Fibrosis in MVP and Non-MVP Patients



Danai Kitkungvan et al. JACC 2016;72:823-834

## ARRHYTHMIC EVENTS AND MVP:

**ARRHYTHMIC EVENTS** Danai Kitkungvan et al. JACC 2018.




PATIENTS WITH MVP AND REPLACEMENT FIBROSIS HAD THE HIGHEST RATE OF ARRHYTHMIC EVENTS



## TYPES OF MITRAL REGURGITATION


### Mitral Regurgitation

#### Primary MR





Anatomic abnormality of the mitral valve

#### Secondary MR




Abnormality of the myocardium NOT valve

## Prognosis in Ischemic Secondary MR Is Influenced by MRF and Infarct Size




Cavalcante et al, JACC Cardiovascular Imaging 2019

## OUTLINE:



[www.med.uottawa.ca](http://www.med.uottawa.ca)

## Quantification of AI Severity




Lopez-Mattei, Methodist DeBakey Cardiovasc J. 2013 Jul-Sep;9(3):142-8

## Quantification of AI Severity


Aortic Regurgitant Volume =

1. Direct measurement of regurgitant flow
2. Indirect methods:
  - ♦ LVOT FF - Pulmonic Net
  - ♦ LVSV - RVSV



Regurgitant Fraction (%) =

$\frac{\text{AI Regurg Volume}}{\text{AV Flow}}$




• Debl et al, Heart 2008






Table 3 MRI-planimetry of ARO, predictive values






	Cases/total (n)	ARO-cut-off (cm <sup>2</sup> )	ROC-area (95% CI)	Sensitivity/specificity (%)
MRI-AR ≥ III	26/45	0.28	0.99 (0.99 to 1.0)	96/95
CATH-AR ≥ III	21/32	0.28	0.95 (0.85 to 1.0)	90/91
MRI-AR IV	13/45	0.48	0.97 (0.90 to 1.0)	83/97







ARO > 0.28 had more than 90% sensitivity/specificity for 3+ Aortic Regurgitation













## Anatomic Orifice Area and Effective Orifice Area are not the same



Neelakantan Sankrishnan et al. Circulation. 2014;129:244-253


32 pts

First Author (Year)	Principle	Reference Standard	n	r	Mean Difference $\pm$ 1 SD (CMR - Echo)	CMR Reproducibility: Mean Difference $\pm$ 1 SD
Anatomic valve area Juhn <sup>21</sup> (2003)	planimetry	TEE	40	0.96	$0.02 \pm 0.08$ cm <sup>2</sup>	$0.07 \pm 0.06$ cm <sup>2</sup>
Kupfab <sup>22</sup> (2004)	planimetry	TEE	32	...	$0.02 \pm 0.21$ cm <sup>2</sup>	$0.05 \pm 0.04$ cm <sup>2</sup>
Debi <sup>23</sup> (2005)	planimetry	TEE	25	0.86	$0.13 \pm 0.16$ cm <sup>2</sup>	$-0.02 \pm 0.06$ cm <sup>2</sup>
Reant <sup>24</sup> (2006)	planimetry	TEE	39	0.58	$0.01 \pm 0.14$ cm <sup>2</sup>	$0.03 \pm 0.14$ cm <sup>2</sup>
Schlösser <sup>25</sup> (2007)	planimetry	TEE	32	0.82	$0.15 \pm 0.13$ cm <sup>2</sup>	$0.02 \pm 0.07$ cm <sup>2</sup>



Schlösser Eur Radiol (2007) 17: 1284-1290


53 AS patients (AVA<sub>TTE</sub>=0.87±0.44 cm<sup>2</sup>) and 21 controls



$$(Continuity Equation) AVA = \frac{LVOT \text{ area} \times VTI_{LVOT}}{VTI_{Ao}} = \frac{SV_{LVOT}}{VTI_{Ao}}$$

Defrance Circ Cardiovasc Imaging. 2012;5:604-612



128 severe AS, nl EF pts




Continuity equation assesses the effective orifice area (EOA), which is always smaller than the actual anatomic orifice & correlates better with clinical outcome

Barone-Rochette Circ Cardiovasc Imaging. 2013;6:1009-1017

## Goal of Imaging in Valvular Stenosis:



Aortic root dilation and Aortopathy alter surgical management





Bicuspid Aortic Valve may be associated with Aortopathy and Coarctation

\*\*\* Screen first degree relatives for aneurysms

Subvalvular AS

Planimeter AV  
Anatomic AVA 1.8 cm sq.

AV Vmax 2.3 m/sec

LVOT Vmax 3.9 m/sec

V<sub>max</sub> = 4 m/sec

Goal of Imaging in Valvular Stenosis:

Severity  
Velocity and Valve Area

Mechanism  
Bicuspid

Consequence  
Volumes & function

LV viability & Contractile Reserve

CMR in casts of cadaveric hearts



Rehr RB. Radiology 1985;156:717-9

CMR volumetry validated:

- Animals
- In vitro
- In vivo
- Ex vivo

Superior to ECHO

- Highly accurate
- Highly reproducible
- Low intra-observer variability
- Low inter-observer variability
- Low inter-study variability






HOUSTON  
**Methodist**  
DEBAKEY HEART & VASCULAR CENTER


**TABLE 3. CMR Data**

	Stented (n=23)		Stentless (n=15)	
	Preoperative	6 Months	Preoperative	6 Months
LVMI, g/m <sup>2</sup>	129±46	104±45	134±41	100±28
LV mass, g	244±94	195±87	244±76	183±53
Ejection fraction, %	68±15	71±11	69±19	76±12
LV end-diastolic volume, median (interquartile range), mL	129 (100, 197)	109 (88, 149)	134 (95, 194)	99 (82, 123)
LV end-systolic volume, median (interquartile range), mL	35 (23, 69)	31 (21, 49)	29 (15, 113)	22 (11, 32)

Values are mean±SD unless indicated otherwise.

Perez de Arenaza D et al. Circulation 2005;112:2696-2702







HOUSTON  
**Methodist**  
DEBAKEY HEART & VASCULAR CENTER

**Table 4** Cox Regression Multivariate Analysis for All-Cause Mortality

Variable	Hazard Ratio	95% Confidence Interval	p Value
Ejection fraction	0.96	0.94-0.99	0.01
Indexed LVEDV	0.68	0.18-2.61	0.57
Midwall LGE	5.35	1.16-24.56	0.03
Infarct LGE	2.56	0.48-13.64	0.27
Subsequent AVR	0.32	0.13-0.76	0.01

LGE potential to provide additional prognostic information for risk stratification in severe AS patients

Dweck, J Am Coll Cardiol 2011;58:1271-9




HOUSTON  
**Methodist**  
DEBAKEY HEART & VASCULAR CENTER





First Author (Year)	CMR Method	Reference Standard: Method	n	r	Mean Difference $\pm$ 1 SD (CMR - Other Modality)	CMR Reproducibility*: Mean Difference $\pm$ 1 SD
<b>Velocity/gradients</b>						
Mohiaddin <sup>19</sup> (1991)	$\dot{V}_{max}$	TTE: $\dot{V}_{max}$	5	...	$-0.12 \pm 0.27$ m/s	...
Kilner <sup>20</sup> (1993)	$\dot{V}_{max}$	TTE: $\dot{V}_{max}$	26†	...	$0.10 \pm 0.46$ m/s	$0.11 \pm 0.29$ m/s†
Hartlala <sup>21</sup> (1993)	E velocity	TTE: E velocity	10§	0.68	...	$0.16\% \pm$
	A velocity	TTE: A velocity		0.83		$0.68\% \pm$
Heidenreich <sup>22</sup> (1995)	peak $\Delta P$	TTE: peak $\Delta P$	14	0.89	$V_{max}$ : $0.38 \pm 0.2$ m/s (Echo - CMR)	$0.001$ m/s†
	mean $\Delta P$	TTE: mean $\Delta P$		0.95		
<b>Valve areas</b>						
Lin <sup>23</sup> (2004)	TVs, T2	TTE: TVs	17	0.86	$0.5 \pm 0.59$ cm <sup>2</sup>	$r = 0.96 \pm$
Djavidani <sup>24</sup> (2005)	planimetry	TTE: TVs	22	0.81	$0.13 \pm 0.24$ cm <sup>2</sup>	$0.03 \pm 0.01$ cm <sup>2</sup>
		catheterization: Gorlin	17	0.89	$0.08 \pm 0.22$ cm <sup>2</sup>	$0.04 \pm 0.02$ cm <sup>2</sup>
Djavidani <sup>25</sup> (2006)	planimetry**	TTE: TVs	13	0.98	$0.03 \pm 0.09$ cm <sup>2</sup>	...
		catheterization: Gorlin	13	0.95	$0.13 \pm 0.15$ cm <sup>2</sup>	

Atrial fibrillation reduces accuracy of the flow measurements

Cawley, Circulation. 2009;119:468-478



HOUSTON  
Methodist  
DEBAKEY HEART & VASCULAR CENTER



Dilated PA's

LAA thrombus

Anatomic MVA 0.9 cm sq.

HOUSTON  
Methodist  
DEBAKEY HEART & VASCULAR CENTER

VALVULAR DYSFUNCTION

Thank You For Your Attention

DISORDERS

Paravalvular Regurgitation

Eccentric Regurgitant Jets

Multiple Regurgitant Jets

Serial Assessments of RVol

Discrepancy Btw PE, 2D, Doppler

Suboptimal Echo Windows

Multiple Valvular Lesions

Assessment of LV volumes & EF

Valve Morphology (Bicuspid)

Suboptimal Doppler Alignment

Discrepancy Between Velocity and Area

Thoracic Aorta

Subvalvular or Supravalvular Obstruction